Better Health, Brighter FutureNews Release
Notice Regarding Pricing of Hybrid Bonds to Repay Senior Short Term Loan
(Offering of Subordinated Bonds)
OSAKA, JAPAN, May 31, 2019 – Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK)(“Takeda”) announced that its hybrid bonds (subordinated bonds) (the “Hybrid Bonds”) with an aggregate
principal amount of 500 billion Japanese yen were priced today.
The proceeds from this Hybrid Bond offering will be used to repay the existing Senior Short Term Loan (the“SSTL”) with an aggregate principal amount of 500 billion Japanese yen drawn down on January 11, 2019.
Costa Saroukos, Chief Financial Officer of Takeda said, “This Hybrid bond issuance is to replace all of theexisting Senior Short Term Loan and will not increase debt outstanding in total. This replacement completes
the permanent financing process related to the Shire Acquisition and supports our intention to keep ourinvestment grade rating. We are fully committed to successfully achieving our deleveraging timeframe andour target net debt / adjusted EBITDA ratio of 2x in 3 to 5 years."
1. Overview of Hybrid Bonds

1. Issue Amount

500 Billion Japanese yen

2. Interest Rate

1.72% per annum (Note 1)

3. Issue Date

June 6, 2019

4. Maturity Date

9. RatingJune 6, 2079
October 6, 2019, for the first payment and thereafter semi-annually April 6
and October 6 of each year (or, in the case of an early redemption, the early
redemption date)
Takeda may redeem the Hybrid Bonds at its discretion on each interest
payment date from and including October 6, 2024 or in case where a Tax
Event or an Equity Credit Change Event occurs.
Takeda may, at its discretion, defer all or some of the payment of interest on
the Hybrid Bonds, subject to mandatory payment clauses.
In liquidation proceedings, bankruptcy proceedings, reorganization
proceedings, rehabilitation proceedings and similar proceedings inaccordance with laws other than the laws of Japan, the Hybrid Bonds will be
subordinate to all senior indebtedness of Takeda and will rank substantiallypari passu with the most senior preferred shares of Takeda and senior to theordinary shares of Takeda.
A－(Japan Credit Rating Agency, Ltd.)

10. Equity Credit

50% (Japan Credit Rating Agency, Ltd. and S&P Global Ratings Japan Inc.)

5. Interest Payment Dates
6. Early Redemption
7. Deferral of Interest Payment
8. Subordination

Notes.
1

1. Subject to step-ups from the day immediately following October 6, 2029 and 2044.
2. For the detailed terms of the Hybrid Bonds, please see the Attachment 1 hereto.
2. Note for Investors
Replacement restrictions described below do not any form part of the terms and conditions of the Hybrid
Bonds, and do not constitute legal or contractual obligations of Takeda.
In the case that the bonds are to be redeemed or bought back before thematurity, it is assumed that the Hybrid Bonds is being replaced with thefinancial instruments that has equivalent equity credit; provided, however,that Takeda may not make such replacement in the defined cases.
For more details of the financing restrictions, please see Attachment 2 hereto.

Replacement restrictions

2

This announcement has been prepared to publicly disclose the offering of the Hybrid Bonds and is notintended to, and does not, constitute, represent or form part of any offer, invitation or solicitation of an offer
to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of, any securities whether pursuant tothis announcement or otherwise.
This document does not constitute an offer to sell or a solicitation of an offer to purchase any securities
within the United States. The Hybrid Bonds have not been and will not be registered under the U.S.
Securities Act of 1933 (the “Act”) and may not be offered or sold in the United States absent registration oran applicable exemption from the registration requirements of the Act. No Hybrid Bonds will be offered in
the United States.
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven
biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future
to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four
therapeutic areas: Oncology, Gastroenterology (GI), Rare Diseases and Neuroscience. We also make targeted
R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly
innovative medicines that contribute to making a difference in people's lives by advancing the frontier of
new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create arobust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients andto working with our partners in health care in approximately 80 countries and regions.
For more information, visit https://www.takeda.com
Investor Relations Contact:
Takashi Okubo
takeda.ir.contact@takeda.com+81 3 3278 2306
Media Inquiries:
Outside of Japan
Tsuyoshi Tada
Tsuyoshi.Tada@takeda.com+1 617 551 2933

Japanese Media:
Kazumi Kobayashi
kazumi.kobayashi@takeda.com+81 (0) 3-3278-2095

Forward-Looking Statements
This press release and any materials distributed in connection with this press release may containforward-looking statements, beliefs or opinions regarding Takeda’s future business, future position andresults of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation,
forward looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”,“expects”, “aims”, “intends”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects”
or words or terms of similar substance or the negative thereof. Any forward-looking statements in thisdocument are based on the current assumptions and beliefs of Takeda in light of the information currently
available to it.

Such forward-looking statements do not represent any guarantee by Takeda or its
3management of future performance and involve known and unknown risks, uncertainties and other factors,
including but not limited to: the economic circumstances surrounding Takeda’s business, including general
economic conditions in Japan, the United States and worldwide; competitive pressures and developments;
applicable laws and regulations; the success of or failure of product development programs; decisions ofregulatory authorities and the timing thereof; changes in exchange rates; claims or concerns regarding thesafety or efficacy of marketed products or products candidates; and post-merger integration with acquiredcompanies, any of which may cause Takeda’s actual results, performance, achievements or financial position
to be materially different from any future results, performance, achievements or financial position expressedor implied by such forward-looking statements.

For more information on these and other factors which

may affect Takeda’s results, performance, achievements, or financial position, see “Item 3. Key
Information—D. Risk Factors” in Takeda’s Registration Statement on Form 20-F and other filings filed with
the

U.S.

Securities

andExchange

Commission,

availableon

https://www.takeda.com/investors/reports/sec-filings/ or at www.sec.gov.

Takeda’s

websiteat:

Neither Takeda nor its

management gives any assurances that the expectations expressed in these forward-looking statements willturn out to be correct, and actual results, performance or achievements could materially differ fromexpectations.

Persons receiving this press release should not place undue reliance on forward looking

statements. Takeda undertakes no obligation to update any of the forward-looking statements contained inthis press release or any other forward-looking statements it may make.

Past performance is not anindicator of future results and the results of Takeda in this press release may not be indicative of, and are notan estimate, forecast or projection of Takeda’s future results.

4

Attachment 1:
This document does not constitute an offer to sell or a solicitation of an offer to purchase any securities
within the United States. The Hybrid Bonds have not been and will not be registered under the U.S. Securities
Act of 1933 (the “Act”) and may not be offered or sold in the United States absent registration or an
applicable exemption from the registration requirements of the Act. No Hybrid Bonds will be offered in the
United States.
Summary of proposed terms and conditions for reference purposes only.

1. Aggregate issued amount of the Hybrid Bonds¥500,000,000,000, in increments of ¥ 100,000,000
2. Rate of interest(1) A fixed rate per annum, during the period beginning the day after June 6, 2019 until and including
October 6, 2024.
(2) Yen LIBOR (subject to adjustment in accordance with the terms and conditions of the Hybrid Bonds)
plus 1.75%, during the period beginning the day after October 6, 2024 until and including October 6,
2029.
(3) Yen LIBOR plus 2.00%, during the period beginning the day after October 6, 2029 until and including
October 6, 2044.
(4) Yen LIBOR plus 2.75%, during the period beginning the day after October 6, 2044.
3. Issue price
100 yen per 100 yen of the principal amount of each Bond
4. Security/guarantee
The Hybrid Bonds are not subject to any security or guarantee, and there are no assets specially reserved.
5. Redemption(1) Redemption at maturity
At par on June 6, 2079 (the “Maturity Date”) together with accrued interest up to such date and any
Optional Outstanding Payment Amount (as defined below).

(2) Early redemption(I) Early redemption at the option of the Company
On October 6, 2024 (the “First Optional Redemption Date”) and each Interest Payment Date(as defined below) on and after the Optional Redemption Date (each, an “Optional
Redemption Date”), the Company may, at its option, redeem early all, but not a portion, of theprincipal of the Hybrid Bonds then outstanding at par, together with accrued interest up to such
Optional Redemption Date and any Optional Outstanding Payment Amount.
5

(II) Early redemption upon occurrence of Tax Events
If a Tax Event (as defined below) has occurred on or after the date of payment for the Hybrid
Bonds and is continuing, the Company may, at its option, redeem all, but not a portion, of theprincipal of the Hybrid Bonds then outstanding on the date fixed by the Company for such
early redemption (the “Tax Redemption Date”), (i) in the case such Tax Redemption Date falls
on and before (and excluding) the First Optional Redemption Date, at a rate of 101 yen per
100 yen of the principal amount of each Hybrid Bond or (ii) in the case such Tax Redemption
Date falls on and after the First Optional Redemption Date, at par, together with the accrued
interest up to the Tax Redemption Date and any Optional Outstanding Payment Amount.
A “Tax Event” shall be deemed to occur if the Company suffers a significant tax disadvantage
by Japanese laws or regulations, or application or interpretation thereof, including such thatinterest on the Hybrid Bonds shall not qualify as deductible expenses in the calculation of
corporate tax imposed on the Company under Japanese tax law, which disadvantage cannot be
avoided by the Company’s reasonable endeavours.

(III) Early redemption upon occurrence of Equity Credit Change Events
If an Equity Credit Change Event (as defined below) has occurred and is continuing, theCompany may, at its option, redeem all, but not a portion, of the Hybrid Bonds thenoutstanding on the date fixed by the Company for such early redemption (the “Equity Credit
Change Event Redemption Date”), (i) in the case such Equity Credit Change Event
Redemption Date falls on and before (and excluding) the First Optional Redemption Date, at a
rate of 101 yen per 100 yen of the principal amount of each Hybrid Bond or (ii) in the casesuch Equity Credit Change Event Redemption Date falls on and after the First Optional
Redemption Date, at par, together with accrued interest up to the Equity Credit Change Event
Redemption Date and any Optional Outstanding Payment Amount.
An “Equity Credit Change Event” shall be deemed to occur where one or more of thedesignated credit rating agencies decides to treat the Hybrid Bonds as having a lower equity
credit than that assigned to the Hybrid Bonds by each such credit rating agency on the date of
the issuance of the Hybrid Bonds due to the revision of such credit rating agency’s standards
for the assignment of equity credit, and a public announcement to that effect has been made ora written notice to that effect has been given to the Company.

6. Method of and limitations on payment of interest(1) Method of payment of interest(I)

The Bonds bear the interest from the date immediately following the date of issuance to the
Maturity Date (or, in the case of an early redemption, to the early redemption date), payable onan Interest Payment Date, in respect of each relevant period beginning on the date immediately
following the Interest Payment Date immediately preceding such Interest Payment Date (or, in6

the case where such relevant Interest Payment Date is the first Interest Payment Date, thePayment Date) and ending on such Interest Payment Date (the “Interest Period”).

(2) “Interest Payment Date” means October 6, 2019, for the first payment and thereafter semi-annually
April 6 and October 6 of each year (or, in the case of an early redemption, the early
redemption date).

(3) Optional suspension(I)

Optional suspension of interest payment
On any Interest Payment Date, the Company may, at its option, defer the payment of all or partof the interest on the Hybrid Bonds that would have been payable on such Interest Payment
Date (an “Optional Suspension,” and any amount of interest so deferred and not paid due to an
Optional Suspension, an “Optional Deferred Payment Amount”, and an Interest Payment Dateon which such interest would have become due if the relevant Optional Suspension having notoccurred, an “Optional Deferred Interest Payment Date”). Such Optional Deferred Payment
Amount shall bear interest at the rate of interest as set forth in Paragraph 2 (such interest
amount, “Additional Interest”) falling on and after the day after the Optional Deferred Interest
Payment Date and before the day on which all of the Optional Deferred Payment Amount has
been paid. For the avoidance of doubt, such Additional Interest shall not bear interest itself.

(II)

Optional payment
The Company may, at its option, pay all or part of the Optional Outstanding Payment Amount.
Such payment shall be made to the Bondholders as of the Interest Payment Date of which the
Optional Outstanding Payment Amount is paid.

(III) Mandatory payment(A)

Mandatory payment due to payment in respect of Junior Stock
With respect to an Interest Payment Date, during the period beginning from andincluding the second business day of the month in which the Interest Payment Date
immediately preceding the relevant Interest Payment Date falls and ending on the firstbusiness day of the month in which the relevant Interest Payment Date falls, if theCompany pays any dividend on or, subject to certain exceptions, repurchases or acquires
any of its common stock or other securities junior to the Hybrid Bonds or othersecurities of the Company with the same rank, then the Company shall, to the extent
commercially practicable (as defined in the terms of the Hybrid Bonds), makereasonable endeavors to pay all of the Optional Outstanding Payment Amountoutstanding as of the relevant Interest Payment Date immediately following the end of
the Mandatory Payment Reference Period during which such Junior Stock Mandatory
Payment Event occurred (the “Mandatory Interest Payment Date”) or on the Interest
Payment Date immediately following the Mandatory Interest Payment Date.
7

(B)Mandatory payment due to payment in respect of Equivalent Securities
Notwithstanding the provisions of (I) above, if dividends or interest has been paid inrespect of the securities of the Company with the same rank as the Hybrid Bonds during
the period from the relevant Optional Deferred Interest Payment Date up to the Interest
Payment Date immediately following such Optional Deferred Interest Payment Date, theCompany shall, to the extent commercially practicable, make reasonable endeavors to
pay the Optional Deferred Payment Amount and the Additional Interest thereon in
respect of the relevant Optional Deferred Interest Payment Date on the Interest Payment
Date immediately following such Optional Deferred Interest Payment Date.

7. Financial covenants
The Company is not subject to any financial covenants for the Hybrid Bonds.
8. Special covenants with respect to acceleration of obligations
The payment of the obligations in respect of the Hybrid Bonds shall not be accelerated or become dueand payable except when becoming due and payable pursuant to the provisions of the terms andconditions of the Hybrid Bonds.
9. Subordination clause
In liquidation proceedings, bankruptcy proceedings, corporate reorganization proceedings or civil
rehabilitation proceedings of the Company or any proceedings that are equivalent thereto in accordancewith laws other than Japanese law, each Hybrid Bondholder shall have a liquidation claim under theHybrid Bonds in an amount, per Hybrid Bond, equal to (i) the principal amount of each outstanding
Hybrid Bond held by such Hybrid Bondholder on the date on which the relevant Liquidation Eventoccurs, plus (ii) any Optional Outstanding Payment Amount in respect of each Bond on such date andaccrued interest on such Bond up to and including such date. The Company shall not bear any obligation
to pay to each Bondholder the amount exceeding the total amount of (i) and (ii) above.
Such Liquidation Claims shall become effective only if the Condition for Liquidation Payment (asdefined [in the terms of the Hybrid Bonds]) is satisfied, and, in the case where the Most Preferred Stockexists on the date on which the relevant Liquidation Event (as defined [in the terms of the Hybrid Bonds])
occurs, such Liquidation Claims (including the distribution thereon) shall become payable only to theextent of the Liquidation Preference Amount of Equivalent Subordinated Debt (as defined [in the terms of
the Hybrid Bonds]) of each Bond.
10. Prohibition of changes to the disadvantage of senior creditors
No provisions of the Hybrid Bonds may be changed to the disadvantage of senior creditors, and noagreement on such change shall take effect in any sense or in respect of any person.
11. Prohibition on setoff
Other than in limited situations in which all amounts due under obligations of the Company senior to theHybrid Bonds have been paid in full, the Hybrid Bond holders shall not be entitled to set off their8obligations to the Company against the claims against the Company for the repayment of principal andinterest under the Hybrid Bonds in the case of any liquidation proceedings, bankruptcy proceedings,
corporate reorganization proceedings or civil rehabilitation proceedings of the Company or any
proceedings that are equivalent thereto in accordance with laws other than Japanese law.

9

Attachment 2:（Reference Purpose only）
This document does not constitute an offer to sell or a solicitation of an offer to purchase any securities
within the United States. The Hybrid Bonds have not been and will not be registered under the U.S. Securities
Act of 1933 (the “Act”) and may not be offered or sold in the United States absent registration or an
applicable exemption from the registration requirements of the Act. No Hybrid Bonds will be offered in the
United States.
Replacement Restrictions
The matters described below do not form any part of the terms and conditions of the Hybrid Bonds,
and do not constitute legal or contractual obligations of Takeda.
Takeda has issued the Hybrid Bonds for the purpose of balancing both of its financial soundness andcapital efficiency, and growing sustainably, and therefore, it is assumed that, upon early redemption or
buyback of the Hybrid Bonds, Takeda will replace the Hybrid Bonds with any financial instrumentsthat has received equity credit evaluation equivalent to that of the Hybrid Bonds from the relevant
ratings agencies (Japan Credit Rating Agency, Ltd. and S&P Global Ratings Japan Inc.).
However, upon early redemption or buyback of the Hybrid Bonds, Takeda may not replace the Hybrid
Bonds with such financial instruments in any of the cases where:(i)

The proposed early redemption or buyback does not result in any of Takeda’s key financial
soundness indicators getting worse than that as of March 31, 2019;(ii)

Takeda’s credit rating obtained by S&P Global Rating Japan Inc. is BBB + or higher, andthere is no concern that such rating becomes less than BBB+ as a result of the proposed early
redemption or buyback;(iii)(x) The total amount of the Hybrid Bonds bought back during any consecutive 12 month
period is less than 10% of the original aggregate principal amount of the Hybrid Bonds, or(y) the total amount of the Hybrid Bonds bought back during any consecutive 10 year period
is less than 25% of the original aggregate principal amount of the Hybrid Bonds;(iv)

The Hybrid Bonds are to be redeemed as a result of occurrence of a Tax Events or an Equity
Credit Change Event (limited to the event where any relevant credit rating agency changes
its requirements for equity credit evaluation);(v)

Both of the relevant credit rating agencies cease to provide their equity credit evaluation (orany other similar evaluation) on the Hybrid Bond; or(vi)

The market function has been stopped due to, among other things, the closure of any major
stock exchange; provided, however, that if either of condition (i) or (ii) above is not met
when the market function recovers, Takeda will be required to promptly replace the Hybrid
Bonds.
10

The replacement shall be made within 360 days before the date of the proposed early redemption or
buyback.

In the case where Takeda or any its subsidiary sells to a third party any securities withequity credit assigned by the relevant credit rating agencies that is equivalent to or better than that of
the Hybrid Bonds, the net proceeds from such sale will be deemed to be the replaced amount inconnection with the replacement of the Hybrid Bonds.

11